P
Pacific GeneTech
Focuses on developing and commercializing vaccines for the livestock industry through their proprietary Aegis platform
About Pacific GeneTech
Pacific GeneTech, founded in 2009 and headquartered in Hong Kong, is a biologics company specializing in the development and commercialization of next-generation vaccines for animal health. The company operates in the global animal health market, focusing on unmet or underserved needs in food safety and animal health. Pacific GeneTech's proprietary Aegis vaccine platform forms the basis for its first-in-class or best-in-class recombinant vaccines, which provide broad protection against multiple strains and species of pathogens. The company partners with multinational and strong regional companies to commercialize its products through out-licensing partnerships, ensuring global distribution and manufacturing capabilities.
Pacific GeneTech's business model involves taking high-value research discoveries from the laboratory through development and regulatory processes to market. The company generates revenue through licensing agreements and joint ventures, such as its collaboration in Southeast Asia to manufacture and distribute the Hercules adjuvant delivery system. Additionally, Pacific GeneTech is working with partners to bring other innovative technologies into its development pipeline.
The company's clients include multinational corporations and regional companies in the animal health industry, as well as research institutions. By addressing critical gaps in the market, Pacific GeneTech aims to enhance food safety and animal health on a global scale.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Hong Kong
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 50.2/100
- Industry
- Health, Food
- Sub-industry
- Pharmaceutical, BioTechnology, AgriTech
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDEquity / VC | Aug 2022 | $10M | $40M | Simmons Foods | ↗ |
| EARLY VC✓Equity / VC | Aug 2022 | $10M | $40M | Medion · Simmons Foods · FHB Ventures · Whist Subholdings | ↗ |
Growth signals
Latest recorded traffic for Pacific GeneTech is 230 monthly website visits, down 76.8% over the last three months. Pacific GeneTech's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Simmons Foods
Series A3 investors entered at this stage
Medion- FVFHB Ventures
- WSWhist Subholdings
Other known investors4 additional known investors
Texas A&M University
The Ohio State University
University of Arkansas
University of Guelph
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pacific GeneTech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pacific GeneTech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.